Agreement in All-in-One Dataset between Diagnosis and Prescribed Medication for Common Cardiometabolic Diseases in the NDB-K7Ps
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Disease Diagnosis, Prescribed Medications, and Self-Reported Medication
2.3. Statistical Analysis
3. Results
3.1. Proportion of Diagnosed Patients among Those Who Were Prescribed Medications
3.2. Proportion of Diagnosed Patients among Those Who Reported Receiving Pharmacotherapy on the Questionnaire
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Brennan, N.; Oelschlaeger, A.; Cox, C.; Tavenner, M. Leveraging the big-data revolution: CMS is expanding capabilities to spur health system transformation. Health Aff. 2014, 33, 1195–1202. [Google Scholar] [CrossRef] [PubMed]
- Kwon, S. Thirty years of national health insurance in South Korea: Lessons for achieving universal health care coverage. Health Policy Plan 2009, 24, 63–71. [Google Scholar] [CrossRef]
- Wu, T.Y.; Majeed, A.; Kuo, K.N. An overview of the healthcare system in Taiwan. Lond. J. Prim. Care 2010, 3, 115–119. [Google Scholar] [CrossRef] [PubMed]
- Kato, G. History of the secondary use of national database of health insurance claims and specific health checkups of Japan(NDB). Trans. Jpn. Soc. Med. Biol. Eng. 2017, 55, 143–150. [Google Scholar] [CrossRef]
- Health Examination and Guidance Program for Japanese Adults (Ministry of Health, Labour and Welfare). Available online: https://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/info02a.html (accessed on 24 September 2023).
- Mongraw-Chaffin, M.L.; Peters, S.A.E.; Huxley, R.R.; Woodward, M. The sex-specific association between BMI and coronary heart disease: A systematic review and meta-analysis of 95 cohorts with 1·2 million participants. Lancet Diabetes Endocrinol. 2015, 3, 437–449. [Google Scholar] [CrossRef]
- Pylypchuk, R.; Wells, S.; Kerr, A.; Poppe, K.; Harwood, M.; Mehta, S.; Grey, C.; Wu, B.P.; Selak, V.; Drury, P.L.; et al. Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: A derivation and validation study. Lancet 2021, 397, 2264–2274. [Google Scholar] [CrossRef] [PubMed]
- Stanciu, S.; Rusu, E.; Miricescu, D.; Radu, A.C.; Axinia, B.; Vrabie, A.M.; Ionescu, R.; Jinga, M.; Sirbu, C.A. Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites 2023, 13, 87. [Google Scholar] [CrossRef] [PubMed]
- Ma, R.C.; Chan, J.C. Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States. Ann. N. Y. Acad. Sci. 2013, 1281, 64–91. [Google Scholar] [CrossRef]
- Study of Seven Kanto Prefectures Using the National Database. Available online: https://mcm-www.jwu.ac.jp/~NDB-K7Ps/blog/?page_id=2 (accessed on 24 September 2023).
- Trends in the Penetration Rate of Electronic Receipts in Medical Institutions (Ministry of Health, Labour and Welfare). Available online: https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000099002.pdf (accessed on 24 September 2023).
- Ando, T.; Ooba, N.; Mochizuki, M.; Koide, D.; Kimura, K.; Lee, S.L.; Setoguchi, S.; Kubota, K. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center. BMC Health Serv. Res. 2018, 18, 895. [Google Scholar] [CrossRef]
- Tamiya, R.; Miyake, M.; Kido, A.; Hiragi, S.; Tamura, H.; Kuroda, T.; Tsujikawa, A. Validation study of the claims-based definition for age-related macular degeneration at a single university hospital in Japan. Jpn. J. Ophthalmol. 2021, 65, 388–394. [Google Scholar] [CrossRef]
- Inspection and Investigation of Health Insurance Claims [Health Insurance Act]. Available online: https://www.mhlw.go.jp/web/t_doc?dataId=00tb4402&dataType=1&pageNo=1 (accessed on 24 September 2023).
- The Japanese Pharmacopoeia 18th Edition. Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000066597.html (accessed on 24 September 2023).
- Pharmaceuticals and Medical Devices Agency. Search System for Prescription Drugs. Available online: https://www.pmda.go.jp/PmdaSearch/iyakuSearch/ (accessed on 24 September 2023).
- Eisenberg, M.J. Accuracy and predictive values in clinical decision-making. Cleve. Clin. J. Med. 1995, 62, 311–316. [Google Scholar] [CrossRef] [PubMed]
- Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903–1913. [Google Scholar] [CrossRef] [PubMed]
- Lewington, S.; Whitlock, G.; Clarke, R.; Sherliker, P.; Emberson, J.; Halsey, J.; Qizilbash, N.; Peto, R.; Collins, R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370, 1829–1839. [Google Scholar] [CrossRef] [PubMed]
- Iozzo, P.; Beck-Nielsen, H.; Laakso, M.; Smith, U.; Yki-Järvinen, H.; Ferrannini, E.; European Group for the Study of Insulin Resistance. Independent influence of age on basal insulin secretion in nondiabetic humans. J. Clin. Endocrinol. Metab. 1999, 84, 863–868. [Google Scholar] [CrossRef]
- Basu, R.; Breda, E.; Oberg, A.L.; Powell, C.C.; Dalla Man, C.; Basu, A.; Vittone, J.L.; Klee, G.G.; Arora, P.; Jensen, M.D.; et al. Mechanisms of the age-associated deterioration in glucose tolerance: Contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003, 52, 1738–1748. [Google Scholar] [CrossRef]
- Claim Status of Receipts in Medical Institutions (April 2018 to March 2019) (Health Insurance Claims Review & Reimbursement Services). Available online: https://www.ssk.or.jp/tokeijoho/tokeijoho_rezept/tokeijoho_rezept_h30.html (accessed on 24 September 2023).
- Nakajima, K.; Sekine, A. Relationship between non-restorative sleep and body weight in a general population: Results of NDB-K7Ps-Study-1. Obes. Res. Clin. Pract. 2023, 17, 171–173. [Google Scholar] [CrossRef]
- Teramoto, T.; Sasaki, J.; Ueshima, H.; Egusa, G.; Kinoshita, M.; Shimamoto, K.; Daida, H.; Biro, S.; Hirobe, K.; Funahashi, T.; et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler. Thromb. 2007, 14, 45–50. [Google Scholar] [CrossRef]
- The Implementation Status of Specific Health Checkups and Guidance in 2020 (Ministry of Health, Labour and Welfare). Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_25882.html (accessed on 24 September 2023).
- Khan, A.; Ramsey, K.; Ballard, C.; Armstrong, E.; Burchill, L.J.; Menashe, V.; Pantely, G.; Broberg, C.S. Limited Accuracy of Administrative Data for the Identification and Classification of Adult Congenital Heart Disease. J. Am. Heart Assoc. 2018, 7, e007378. [Google Scholar] [CrossRef]
- Oake, J.; Aref-Eshghi, E.; Godwin, M.; Collins, K.; Aubrey-Bassler, K.; Duke, P.; Mahdavian, M.; Asghari, S. Using Electronic Medical Record to Identify Patients with Dyslipidemia in Primary Care Settings: International Classification of Disease Code Matters from One Region to a National Database. Biomed. Inform. Insights 2017, 9, 1178222616685880. [Google Scholar] [CrossRef]
- Cheng, C.L.; Lee, C.H.; Chen, P.S.; Li, Y.H.; Lin, S.J.; Yang, Y.H. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J. Epidemiol. 2014, 24, 500–507. [Google Scholar] [CrossRef]
- Kern, D.M.; Davis, J.; Williams, S.A.; Tunceli, O.; Wu, B.; Hollis, S.; Strange, C.; Trudo, F. Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. Int. J. Chronic Obstr. Pulm. Dis. 2015, 10, 1417–1425. [Google Scholar] [CrossRef] [PubMed]
- Okui, T.; Nojiri, C.; Kimura, S.; Abe, K.; Maeno, S.; Minami, M.; Maeda, Y.; Tajima, N.; Kawamura, T.; Nakashima, N. Performance evaluation of case definitions of type 1 diabetes for health insurance claims data in Japan. BMC Med. Inform. Decis. Mak. 2021, 21, 52. [Google Scholar] [CrossRef] [PubMed]
- Ishimaru, M.; Ono, S.; Morita, K.; Matsui, H.; Hagiwara, Y.; Yasunaga, H. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan. J. Oral Maxillofac. Surg. 2022, 80, 714–727. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, R.M.; Chambers, D.A.; Glasgow, R.E. Big data and large sample size: A cautionary note on the potential for bias. Clin. Transl. Sci. 2014, 7, 342–346. [Google Scholar] [CrossRef]
Names of Diagnoses | Corresponding ICD-10 Code | Medications | Patients with Diagnosis/ Patients with Prescription, N (%) | ||||
---|---|---|---|---|---|---|---|
Trade Name | Nonproprietary Name 1 | Therapeutic Category | |||||
Hypertension 2 | I10 | Perdipine (Powder 10%, Tablets 10 mg/20 mg, LA Capsules 20 mg/40 mg, Injection 2 mg/5 mg/25 mg) | Nicardipine hydrochloride | Dihydropyridine calcium channel blocker | 731/748 (97.7) | ||
Valsartan Tablets 20 mg (generic) 3 | Valsartan | Angiotensin II receptor antagonist | 7332/7423 (98.8) | ||||
RENIVACE Tablets 2.5 mg/5 mg/10 mg | Enalapril Maleate | Angiotensin-converting enzyme inhibitor | 5506/5796 (95.0) | ||||
NU-LOTAN Tablets 25 mg/50 mg/100 mg | Losartan Potassium | Angiotensin II receptor antagonist | 11,189/11,346 (98.6) | ||||
Mikelan LA capsules 15 mg | Carteolol Hydrochloride | Beta-Adrenergic receptor antagonist (Beta blocker) | 726/737 (98.5) | ||||
CALSLOT TABLETS 5 mg/10 mg/20 mg | Manidipine Hydrochloride | Dihydropyridine calcium channel blocker | 1308/1328 (98.5) | ||||
Selara Tablets 25 mg/50 mg/100 mg | Eplerenone | Mineralocorticoid receptor antagonist | 19,099/19,425 (98.3) | ||||
PREMINENT Tablets LD/HD | Losartan Potassium/ Hydrochlorothiazide | Angiotensin II receptor blockers (ARBs) and diuretics | 5509/5589 (98.6) | ||||
Patients who were prescribed at least 1 of the above 8 antihypertensive medications | |||||||
Medication | |||||||
n (% column) | yes | no | |||||
Diagnosis | yes | 50,620 (98.1) | 2,319,001 (22.9) | ||||
no | 978 (1.9) | 7,813,020 (77.1) | Accuracy (%) * = 77.2% | ||||
Diabetes (except for gestational diabetes) 4 | E10~14, E888 | METGLUCO Tablets 250 mg | Metformin Hydrochloride | Biguanide antidiabetic | 80,921/81,290 (99.5) | ||
TENELIA TABLETS 20 mg | Teneligliptin Hydrobromide Hydrate | DPP-4 inhibitor | 34,691/34,849 (99.5) | ||||
Suglat Tablets 25 mg | Ipragliflozin L-Proline | SGLT2 inhibitor | 4936/4964 (99.4) | ||||
Patients who were prescribed at least 1 of the above 3 antidiabetic medications | |||||||
Medication | |||||||
n (% column) | yes | no | |||||
Diagnosis | yes | 114,067 (99.5) | 1,179,420 (11.7) | ||||
no | 530 (0.5) | 8,889,602 (88.3) | Accuracy (%) * = 88.4% | ||||
Dyslipidemia | E785 | LIVALO OD TABLETS 2 mg | Pitavastatin Calcium Hydrate | HMG-CoA reductase inhibitor | 2158/7767 (27.8) | ||
BEZATOL SR Tab. 200 mg | Bezafibrate | Fibrate (PPAR alpha agonist) | 2987/10,768 (27.7) | ||||
Zetia Tablets 10 mg | Ezetimibe | Intestinal cholesterol transporter inhibitor | 28,702/101,270 (28.3) | ||||
Hypercholesterolemia (including familial hypercholesterolemia) | E780 | LIVALO OD TABLETS 2 mg | Pitavastatin Calcium Hydrate | HMG-CoA reductase inhibitor | 5144/7767 (64.6) | ||
BEZATOL SR Tab. 200 mg | Bezafibrate | Fibrate (PPAR alpha agonist) | 2690/10,768 (24.3) | ||||
Zetia Tablets 10 mg | Ezetimibe | Intestinal cholesterol transporter inhibitor | 64,524/101,270 (61.3) | ||||
Hyperlipidemia | E784, E785 | LIVALO OD TABLETS 2 mg | Pitavastatin Calcium Hydrate | HMG-CoA reductase inhibitor | 3073/7767 (39.6) | ||
BEZATOL SR Tab. 200 mg | Bezafibrate | Fibrate (PPAR alpha agonist) | 7637/10,768 (70.9) | ||||
Zetia Tablets 10 mg | Ezetimibe | Intestinal cholesterol transporter inhibitor | 45,016/101,270 (44.5) | ||||
Dyslipidemia, hypercholesterolemia (including familial hypercholesterolemia), or hyperlipidemia | E780, E784, E785 | LIVALO OD TABLETS 2 mg | Pitavastatin Calcium Hydrate | HMG-CoA reductase inhibitor | 7685/7767 (98.9) | ||
BEZATOL SR Tab. 200 mg | Bezafibrate | Fibrate (PPAR alpha agonist) | 10,415/10,768 (96.7) | ||||
Zetia Tablets 10 mg | Ezetimibe | Intestinal cholesterol transporter inhibitor | 99,462/101,270 (98.2) | ||||
Patients who were prescribed at least 1 of the above 3 medications for dyslipidemia | |||||||
Medication | |||||||
n (% column) | yes | no | |||||
Diagnosis | yes | 115,724 (98.1) | 2,219,921 (22.1) | ||||
no | 2206 (1.9) | 7,845,768 (78.0) | Accuracy (%) * = 78.2% | ||||
Hyperuricemia | E790 | Zyloric Tablets 50 mg/100 mg | Allopurinol | Uric acid biosynthesis inhibitor | 13,788/17,407 (79.2) | ||
Feburic Tablets 10 mg/20 mg/40 mg | Febuxostat | Uric acid biosynthesis inhibitor | 216,363/260,753 (83.0) | ||||
Gout (including gouty attack) | M1009 | Zyloric Tablets 50 mg/100 mg | Allopurinol | Uric acid biosynthesis inhibitor | 5909/17,407 (33.9) | ||
Feburic Tablets 10 mg/20 mg/40 mg | Febuxostat | Uric acid biosynthesis inhibitor | 80,855/260,753 (31.0) | ||||
Hyperuricemia or gout | E790, M1009 | Zyloric Tablets 50 mg/100 mg | Allopurinol | Uric acid biosynthesis inhibitor | 17,042/17,407 (97.9) | ||
Feburic Tablets 10 mg/20 mg/40 mg | Febuxostat | Uric acid biosynthesis inhibitor | 257,621/260,753 (98.8) | ||||
Patients who were prescribed at 1 least the above 2 medications for hyperuricemia and gout | |||||||
Medication | |||||||
n (% column) | yes | no | |||||
Diagnosis | yes | 273,685 (98.7) | 472,650 (4.8) | ||||
no | 3488 (1.3) | 9,433,796 (95.2) | Accuracy (%) * = 95.3% | ||||
Vitamin K deficiency 5 | E561, D684 | Glakay capsules 15 mg | Menatetrenone | Vitamin K2 preparations/ Osteoporosis agent | 39/2084 (1.9) | ||
Kaytwo (Capsules 5 mg, Syrup 0.2%, Injection 10 mg) | Vitamin K2 preparations | 25/41 (61.0) | |||||
Osteoporosis | M8199 | Glakay capsules 15 mg | Menatetrenone | Vitamin K2 preparations/ Osteoporosis agent | 1919/2084 (92.1) | ||
Kaytwo (Capsules 5 mg, Syrup 0.2%, Injection10 mg) | Vitamin K2 preparations | — 7 (<20) | |||||
Vitamin E deficiency | E560 | Juvela (Tablets 50 mg, Capsules 100 mg/200 mg, Powder 20%/40%) | Tocopherol acetate | Vitamin E preparations | 1090/38,085 (2.9) | ||
Arteriosclerosis | I709 | 1361/38,085 (3.6) | |||||
Diabetic retinopathy 6 | E103, E113, E143 | 930/38,085 (2.4) |
Questionnaire of Specific Health Checkups | Names of Diagnoses | Corresponding ICD-10 Code | Patients with Diagnosis/Patients Reported Receiving Pharmacotherapy, N (%) † | |||||
---|---|---|---|---|---|---|---|---|
Sex | Age Groups (Years Old) | |||||||
Are You Taking Following Medicines at Present? | Men (M) | Women(W) | 40–49 | 50–59 | 60–69 | 70–74 | ||
Q1. Medications to reduce blood pressure | Hypertension 1 | I10 | 1,137,463/1,245,659 (91.3) * | 697,913/737,123 (94.7) * | 187,774/208,968 (89.9) * | 474,685/523,370 (90.7) | 1,172,917/1,250,444 (93.8) | 483,587/509,394 (94.9) * |
Self-reported medication | ||||||||
n (% column) | yes | no | ||||||
Diagnosis | yes | 1,835,376 (92.6) | 533,544 (6.5) | |||||
no | 147,406 (7.4) | 7,662,184 (93.5) | Accuracy (%) ‡ = 93.3 | |||||
Q2. Insulin injection or medications to reduce blood glucose | Diabetes 2 | E10-14, E888 | 347,215/374,024 (92.8) * | 133,202/141,612 (94.1) * | 64,010/69,910 (91.6) * | 133,200/144,054 (92.5) | 283,207/301,672 (93.9) | 109,367/115,696 (94.5) * |
Self-reported medication | ||||||||
n (% column) | yes | no | ||||||
Diagnosis | yes | 480,417 (93.2) | 812,594 (8.4) | |||||
no | 35,219 (6.8) | 8,849,877 (91.6) | Accuracy (%) ‡ = 91.7 | |||||
Q3. Medications to reduce your cholesterol level | Dyslipidemia | E785 | 167,983/696,340 (24.1) * | 150,248/645,362 (23.3) * | 34,403/136,446 (25.2) | 81,884/334,244 (24.5) | 201,944/871,012 (23.2) | 82,534/357,397 (23.1) |
Hypercholesterolemia 3 | E780 | 323,350/696,340 (46.4) * | 335,639/645,362 (52.0) * | 64,300/136,446 (47.1) | 162,899/334,244 (48.7) | 442,912/871,012 (50.9) | 183,445/357,397 (51.3) | |
Hyperlipidemia | E784, E785 | 297,583/696,340 (42.7) * | 271,638/645,362 (42.1) * | 52,842/136,446 (38.7) | 134,382/334,244 (40.2) | 381,997/871,012 (43.9) | 162,022/357,397 (45.3) | |
Dyslipidemia, hypercholesterolemia, or hyperlipidemia | E780, E784, E785 | 623,231/696,340 (89.5) * | 607,909/645,362 (94.2) * | 119,709/136,446 (87.7) * | 298,862/334,244 (89.4) | 812,569/871,012 (93.3) | 337,510/357,397 (94.4) * | |
Self-reported medication | ||||||||
n (% column) | yes | no | ||||||
Diagnosis | yes | 1,231,140 (91.8) | 1,103,615 (12.5) | |||||
no | 110,562 (8.2) | 7,732,880 (87.5) | Accuracy (%) ‡ = 88.1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sekine, A.; Nakajima, K. Agreement in All-in-One Dataset between Diagnosis and Prescribed Medication for Common Cardiometabolic Diseases in the NDB-K7Ps. Epidemiologia 2023, 4, 370-381. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia4040034
Sekine A, Nakajima K. Agreement in All-in-One Dataset between Diagnosis and Prescribed Medication for Common Cardiometabolic Diseases in the NDB-K7Ps. Epidemiologia. 2023; 4(4):370-381. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia4040034
Chicago/Turabian StyleSekine, Airi, and Kei Nakajima. 2023. "Agreement in All-in-One Dataset between Diagnosis and Prescribed Medication for Common Cardiometabolic Diseases in the NDB-K7Ps" Epidemiologia 4, no. 4: 370-381. https://0-doi-org.brum.beds.ac.uk/10.3390/epidemiologia4040034